Comment on "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".
作者信息
Salehi-Abargouei Amin, Muka Taulant, Collet Tinh-Hai, Kepp Kasper P, Chatelan Angeline
机构信息
Research Center for Food Hygiene and Safety, Shahid Sadoughi University of Medical Sciences, Alem Square, Yazd, Iran.
Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Alem Square, Yazd, Iran.
出版信息
Alzheimers Dement. 2025 May;21(5):e70035. doi: 10.1002/alz.70035.
Abstract
摘要
相似文献
1
Comment on "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".关于“司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：在美国使用全国范围真实世界数据进行的目标试验模拟”的评论
Alzheimers Dement. 2025 May;21(5):e70035. doi: 10.1002/alz.70035.
2
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟
Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313. Epub 2024 Oct 24.
3
Response to the letter titled reply to "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".对题为《司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟》的信件的回复
Alzheimers Dement. 2025 Feb;21(2):e14611. doi: 10.1002/alz.14611.
4
Response to the letter titled "Comment on associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".对题为“关于司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联的评论：使用美国全国范围真实世界数据进行目标试验模拟”的信件的回复
Alzheimers Dement. 2025 May;21(5):e14581. doi: 10.1002/alz.14581.
5
Reply to "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".对《司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟》的回复
Alzheimers Dement. 2025 Feb;21(2):e14620. doi: 10.1002/alz.14620.
6
Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.在 2 型糖尿病患者中，司美格鲁肽与烟草使用障碍的关联：使用真实世界数据的目标试验模拟。
Ann Intern Med. 2024 Aug;177(8):1016-1027. doi: 10.7326/M23-2718. Epub 2024 Jul 30.
7
Semaglutide (Ozempic) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss.司美格鲁肽（Ozempic）在丹麦2018年至2023年的使用情况——用户趋势及减肥的非标签处方用药情况
Clin Epidemiol. 2024 Apr 25;16:307-318. doi: 10.2147/CLEP.S456170. eCollection 2024.
8
Generating real-world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti-amyloid therapies.在早期阿尔茨海默病中生成真实世界证据：应用目标试验模拟框架研究抗淀粉样蛋白疗法安全性的考量
Alzheimers Dement (N Y). 2025 Apr 15;11(2):e70080. doi: 10.1002/trc2.70080. eCollection 2025 Apr-Jun.
9
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.使用口服司美格鲁肽起始治疗的2型糖尿病患者的真实世界治疗模式
Diabetes Ther. 2024 Jul;15(7):1547-1559. doi: 10.1007/s13300-024-01589-4. Epub 2024 May 9.
10
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).在 2 型糖尿病患者中比较每周一次胰高血糖素样肽-1 受体激动剂（OW GLP-1RAs）与二肽基肽酶-4 抑制剂（DPP-4is）的降糖和减重效果的真实世界疗效（RELATE）。
Clin Drug Investig. 2024 Apr;44(4):271-284. doi: 10.1007/s40261-024-01354-2. Epub 2024 Mar 20.
本文引用的文献
1
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟
Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313. Epub 2024 Oct 24.
2
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.9. 血糖治疗的药物学方法：2024 年糖尿病护理标准。
Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009.
3
Healthcare utilization prior to a diagnosis of young-onset Alzheimer's disease: a nationwide nested case-control study.在诊断为早发性阿尔茨海默病之前的医疗保健利用情况：一项全国性的嵌套病例对照研究。
J Neurol. 2023 Dec;270(12):6093-6102. doi: 10.1007/s00415-023-11974-x. Epub 2023 Sep 5.
4
Diabetic hypertriglyceridaemia and Alzheimer's disease: causal or not?糖尿病性高甘油三酯血症与阿尔茨海默病：是否存在因果关系？
Curr Opin Endocrinol Diabetes Obes. 2022 Apr 1;29(2):101-105. doi: 10.1097/MED.0000000000000696.
5
Time to Diagnosis in Young Onset Alzheimer's Disease: A Population-Based Study from Central Norway.早发性阿尔茨海默病的诊断时间：来自挪威中部的一项基于人群的研究。
J Alzheimers Dis. 2021;82(3):965-974. doi: 10.3233/JAD-210090.
6
Association of body mass index with risk of cognitive impairment and dementia: A systematic review and meta-analysis of prospective studies.体重指数与认知障碍和痴呆风险的关联：前瞻性研究的系统评价和荟萃分析
Neurosci Biobehav Rev. 2020 Aug;115:189-198. doi: 10.1016/j.neubiorev.2020.05.012. Epub 2020 May 30.
7
Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research.倾向评分法在观察性队列研究中控制混杂因素的应用：统计入门及在内镜研究中的应用。
Gastrointest Endosc. 2019 Sep;90(3):360-369. doi: 10.1016/j.gie.2019.04.236. Epub 2019 Apr 30.
8
Design and sample size considerations for Alzheimer's disease prevention trials using multistate models.使用多状态模型进行阿尔茨海默病预防试验的设计与样本量考量
Clin Trials. 2019 Apr;16(2):111-119. doi: 10.1177/1740774518816323.
9
Promises and pitfalls of electronic health record analysis.电子健康记录分析的承诺与陷阱。
Diabetologia. 2018 Jun;61(6):1241-1248. doi: 10.1007/s00125-017-4518-6. Epub 2017 Dec 15.
10
Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study.未控制的糖尿病会增加患阿尔茨海默病的风险：一项基于人群的队列研究。
Diabetologia. 2009 Jun;52(6):1031-9. doi: 10.1007/s00125-009-1323-x. Epub 2009 Mar 12.
Zotero 插件